{"id":44025,"date":"2022-05-17T23:01:03","date_gmt":"2022-05-17T21:01:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/"},"modified":"2022-05-17T23:01:03","modified_gmt":"2022-05-17T21:01:03","slug":"emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/","title":{"rendered":"Emendo Biotherapeutics\u2019 next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Emendo Biotherapeutics revealed pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an allele-specific editing approach, generating a highly specific editing composition that achieves both no off-targets and complete allele specificity, in oral presentation at ASGCT annual meeting by Emendo Executive VP R&amp;D Rafi Emmanuel, Ph.D.<\/i>\n<\/li>\n<li>\n<i>Emendo also presented three posters at ASGCT, highlighting applications of Emendo\u2019s non-NGG PAM nuclease in immuno-oncology, a gene editing solution to enhance LDLR expression and boost LDL-C uptake in Familial Hypercholesterolemia, and challenges and inconsistencies in Type II CRISPR-associated nuclease subtype classification<\/i>\n<\/li>\n<\/ul>\n<p>NEW YORK&#8211;(BUSINESS WIRE)&#8211;Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25<sup>th<\/sup> Annual Meeting of the American Society of Gene &amp; Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220517006030\/en\/1458588\/4\/Emendo_Bio_Logo-Color_signature.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220517006030\/en\/1458588\/21\/Emendo_Bio_Logo-Color_signature.jpg\"><\/a><\/p>\n<p>\nEmendo presented pre-clinical data for the treatment of <i>ELANE<\/i>-related Severe Congenital Neutropenia using an allele-specific editing approach, demonstrating the power of Emendo\u2019s dual technology platforms that enable the development of a highly specific editing composition that demonstrates no off-targets and complete allele specificity. Significantly, the lack of off-target achieved by Emendo\u2019s engineered and optimized OMNI nuclease also eliminated any translocations. Edited patient derived CD34+ cells differentiated normally into neutrophils both <i>in-vitro<\/i> and <i>in-vivo<\/i>, showing full engraftment and reconstitution of all blood lineages, as required for the desired therapeutic effect.\n<\/p>\n<p>\n\u201c<i>ELANE<\/i>-based Severe Congenital Neutropenia, Emendo\u2019s lead indication, is a devastating disease affecting pediatric patients that until now has been incurable,\u201d said David Baram, Ph.D., President &amp; CEO of Emendo Biotherapeutics. \u201cWe are excited by the potentially curative treatment developed by our team and were pleased to present our pre-clinical results for this program and other diverse applications of our dual gene editing technology platforms at this year\u2019s ASGCT meeting. And of course, we look forward to the discussion generated by our discoveries around Type II CRISPR nuclease classifications that promise to be ground-breaking in the field.\u201d\n<\/p>\n<p>\nSenior members of the Emendo Biotherapeutics R&amp;D team including Chief Technology Officer Lior Izhar, Ph.D. and Executive Vice-President Research &amp; Development Rafi Emmanuel, Ph.D. presented Emendo\u2019s research on-site at the conference.\n<\/p>\n<p>\n<b>Session Presentation<\/b>\n<\/p>\n<p>\nTitle: A Novel Engineered CRISPR-Associated Nuclease Accurately Removes ELANE Mutated Allele and Shifts HSC Differentiation Towards Neutrophils in Severe Congenital Neutropenia\n<\/p>\n<p>\nSession Title: Gene Therapy for Immunologic Diseases<br \/>\n<br \/>Session Date\/Time: Tuesday May 17, 2022 3:45 PM &#8211; 5:30 PM<br \/>\n<br \/>Presentation Time: 3:45pm &#8211; 4:00pm<br \/>\n<br \/>Room: Room 202<br \/>\n<br \/>Final abstract number: 482\n<\/p>\n<p>\n<b>Poster Presentations<\/b>\n<\/p>\n<p>\nTitle: A Unique CRISPR-Based Nuclease with a Non-NGG PAM Efficiently Targets Multiple Exclusive Genomic Sites for Immuno-Oncology Based Therapy\n<\/p>\n<p>\nSession Title: Cancer &#8211; Targeted Gene and Cell Therapy I<br \/>\n<br \/>Session Date\/Time: Monday May 16, 2022 5:30 PM &#8211; 6:30 PM<br \/>\n<br \/>Poster Board Number: M-215<br \/>\n<br \/>Room: Hall D<br \/>\n<br \/>Final abstract number: 334\n<\/p>\n<p>\nTitle: CRISPR-Based Gene Editing Enhances LDLR Expression and Boosts LDL-C Uptake in Familial Hypercholesterolemia\n<\/p>\n<p>\nSession Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases II<br \/>\n<br \/>Session Date\/Time: Wednesday May 18, 2022 5:30 PM &#8211; 6:30 PM<br \/>\n<br \/>Poster Board Number: W-125<br \/>\n<br \/>Room: Hall D<br \/>\n<br \/>Final abstract number: 999\n<\/p>\n<p>\nTitle: Challenges and Inconsistencies in Type II CRISPR-Associated Nuclease Subtype Classification\n<\/p>\n<p>\nSession Title: Gene Targeting and Gene Correction II<br \/>\n<br \/>Session Date\/Time: Tuesday May 17, 2022 5:30 PM &#8211; 6:30 PM<br \/>\n<br \/>Poster Board Number: Tu-61<br \/>\n<br \/>Room: Hall D<br \/>\n<br \/>Final abstract number: 556\n<\/p>\n<p>\n<b>About Emendo Biotherapeutics<\/b>\n<\/p>\n<p>\nEmendo Biotherapeutics, a subsidiary of AnGes, Inc., is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. Emendo\u2019s novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, including allele specific editing, while maintaining high efficiencies. The capabilities of the OMNI technology platforms, along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide Emendo with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas. For more information please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.emendobio.com&amp;esheet=52722286&amp;newsitemid=20220517006030&amp;lan=en-US&amp;anchor=www.emendobio.com&amp;index=1&amp;md5=295e02b47febf9b8512c4fd9a72f20f8\" rel=\"nofollow noopener\" shape=\"rect\">www.emendobio.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b><span class=\"bwuline\">Media:<\/span><\/b><br \/>Shahar Avni<br \/>\n<br \/>Business Development Specialist<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x73;h&#97;&#x68;a&#114;&#x61;&#64;&#x65;&#x6d;&#101;&#x6e;&#x64;&#111;&#x62;i&#111;&#x2e;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">shah&#97;&#114;&#97;&#64;&#101;&#x6d;&#x65;&#x6e;&#x64;&#x6f;&#x62;&#x69;o&#46;co&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Emendo Biotherapeutics revealed pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an allele-specific editing approach, generating a highly specific editing composition that achieves both no off-targets and complete allele specificity, in oral presentation at ASGCT annual meeting by Emendo Executive VP R&amp;D Rafi Emmanuel, Ph.D. Emendo also presented three posters at ASGCT, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44025","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Emendo Biotherapeutics\u2019 next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emendo Biotherapeutics\u2019 next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Emendo Biotherapeutics revealed pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an allele-specific editing approach, generating a highly specific editing composition that achieves both no off-targets and complete allele specificity, in oral presentation at ASGCT annual meeting by Emendo Executive VP R&amp;D Rafi Emmanuel, Ph.D. Emendo also presented three posters at ASGCT, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-17T21:01:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220517006030\/en\/1458588\/21\/Emendo_Bio_Logo-Color_signature.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Emendo Biotherapeutics\u2019 next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting\",\"datePublished\":\"2022-05-17T21:01:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/\"},\"wordCount\":686,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517006030\\\/en\\\/1458588\\\/21\\\/Emendo_Bio_Logo-Color_signature.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/\",\"name\":\"Emendo Biotherapeutics\u2019 next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517006030\\\/en\\\/1458588\\\/21\\\/Emendo_Bio_Logo-Color_signature.jpg\",\"datePublished\":\"2022-05-17T21:01:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517006030\\\/en\\\/1458588\\\/21\\\/Emendo_Bio_Logo-Color_signature.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517006030\\\/en\\\/1458588\\\/21\\\/Emendo_Bio_Logo-Color_signature.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Emendo Biotherapeutics\u2019 next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emendo Biotherapeutics\u2019 next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/","og_locale":"en_US","og_type":"article","og_title":"Emendo Biotherapeutics\u2019 next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting - Pharma Trend","og_description":"Emendo Biotherapeutics revealed pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an allele-specific editing approach, generating a highly specific editing composition that achieves both no off-targets and complete allele specificity, in oral presentation at ASGCT annual meeting by Emendo Executive VP R&amp;D Rafi Emmanuel, Ph.D. Emendo also presented three posters at ASGCT, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-17T21:01:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220517006030\/en\/1458588\/21\/Emendo_Bio_Logo-Color_signature.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Emendo Biotherapeutics\u2019 next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting","datePublished":"2022-05-17T21:01:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/"},"wordCount":686,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220517006030\/en\/1458588\/21\/Emendo_Bio_Logo-Color_signature.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/","url":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/","name":"Emendo Biotherapeutics\u2019 next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220517006030\/en\/1458588\/21\/Emendo_Bio_Logo-Color_signature.jpg","datePublished":"2022-05-17T21:01:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220517006030\/en\/1458588\/21\/Emendo_Bio_Logo-Color_signature.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220517006030\/en\/1458588\/21\/Emendo_Bio_Logo-Color_signature.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/emendo-biotherapeutics-next-generation-crispr-gene-editing-technologies-achieve-breakthrough-results-with-allele-specific-approach-for-elane-related-severe-congenital-neutropenia-as-presented\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Emendo Biotherapeutics\u2019 next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44025"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44025\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}